Show simple item record

dc.contributor.authorTangen, Ingvild Løbergen_US
dc.contributor.authorKrakstad, Camillaen_US
dc.contributor.authorHalle, Mari Kyllesøen_US
dc.contributor.authorWerner, Henrica Maria Johannaen_US
dc.contributor.authorØyan, Anne Margreteen_US
dc.contributor.authorKusonmano, Kanthidaen_US
dc.contributor.authorPetersen, Kjellen_US
dc.contributor.authorKalland, Karl-Henningen_US
dc.contributor.authorAkslen, Lars A.en_US
dc.contributor.authorTrovik, Joneen_US
dc.contributor.authorRodriguez, Antoni Hurtadoen_US
dc.contributor.authorSalvesen, Helga Birgitteen_US
dc.description.abstractBackground: The transcription factor Forkhead box A1 (FOXA1) is suggested to be important in hormone dependent cancers, although with little data for endometrial cancer. We investigated expression levels of FOXA1 in primary and metastatic endometrial cancer in relation to clinical phenotype, and transcriptional alterations related to FOXA1 status. Methods: Protein expression of FOXA1 was explored by immunohistochemistry in 529 primary and 199 metastatic endometrial carcinoma lesions. mRNA levels from corresponding 158 fresh frozen primary and 42 metastatic lesions were analyzed using Agilent Microarrays (44k) in parallel. Results: Low FOXA1 protein expression in primary tumors significantly correlated with low FOXA1 mRNA, high age, non-endometrioid histology, high grade, loss of ERα and PR and poor survival (all p-values <0.05). Through a Connectivity Map search, HDAC inhibitors were suggested as potential treatment for patients with low FOXA1 expression. An increase in FOXA1 expression was observed from primary to metastatic lesions and it correlated with CDKN2A expression in metastases. Conclusion: Low FOXA1 is associated with poor survival and suggests a potential for HDAC inhibitors in endometrial carcinoma. A switch in FOXA1 expression from primary to metastatic lesions is observed and gene expression indicates a link between FOXA1 and CDKN2A in metastatic lesions.en_US
dc.publisherPublic Library of Scienceeng
dc.rightsAttribution CC BYeng
dc.titleSwitch in FOXA1 status associates with endometrial cancer progressionen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2014 Tangen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
dc.source.journalPLoS ONE
dc.relation.projectNorges forskningsråd: 191778
dc.relation.projectNorges forskningsråd: 223250
dc.relation.projectNorges forskningsråd: 205404
dc.relation.projectNorges forskningsråd: 187615
dc.subject.nsiVDP::Medical sciences: 700::Clinical medical sciences: 750::Endocrinology: 774eng
dc.subject.nsiVDP::Medical sciences: 700::Clinical medical sciences: 750::Oncology: 762eng
dc.subject.nsiVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Endokrinologi: 774nob
dc.subject.nsiVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Onkologi: 762nob

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY